Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hP1A8 and GBM6-AD Vaccine in Recurrent Glioblastoma
NCT04642937Phase 1Unknown
- Sponsor
- OX2 Therapeutics
- Start
- Dec 2020
- Primary completion
- Nov 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hP1A8 in glioblastoma (GBM), sponsored by OX2 Therapeutics. Primary endpoint: Maximum tolerated dose of hP1A8 at 12 months. Status: unknown.
02
Drugs
hP1A8
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04642937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04642937.